Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 2, 2009, Pages 127-136

  Leddy, John J ^b,c   Waxmonsky, James G ^b,c   Salis, Robert J ^b   Paluch, Rocco A ^b   Gnagy, Elizabeth M ^c   Mahaney, Patrick ^b   Erbe, Richard ^b   Pelham, William E ^a,c   Epstein, Leonard H ^b  

^a The State University of New York   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; METHYLPHENIDATE; PLACEBO; PROTEIN SLC6A3; UNCLASSIFIED DRUG;

ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FOOD INTAKE; GENE INTERACTION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STOMACH PAIN;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EATING; FEMALE; GENOTYPE; HUMANS; MALE; METHYLPHENIDATE; MINISATELLITE REPEATS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; WEIGHT LOSS;

EID: 65249135898     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.046     Document Type: Article

References (87)

1. th edition (DSM-IV). Washignton (DC): American Psychiatric Association, 1994.
2. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH: Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 65:1157-1165, 1995.
3. Bannon MJ, Granneman JG, Kapatos G: The dopamine transporter: potential involvement in neuropsychiatric disorders. In: Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer D. New York: Raven Press, 1995, pp 179-188.
4. Baptista T: Body weight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatr Scand 100:3-16, 1999.
5. Berridge KC: Food reward: Brain substrates of wanting and liking. Neurosci Biobehav Rev 20:1-25, 1996.
6. Biederman J, Faraone SV: Current concepts on the neurobiology of attention-deficit/hyperactivity disorder. J Atten Disord 6(Suppl 1):S7-S16, 2002.
7. Biederman J, Faraone SV, Monuteaux MC, Plunkett EA, Gifford J, Spencer T: Growth deficits and attention-deficit/hyperactivity disorder revisited: Impact of gender, development, and treatment. Pediatrics 111:1010-1016, 2003.
8. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL: Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forceddose, parallel-group study. Clin Ther Mar 29:450-463, 2007.
9. Bolanos CA, Barrot M, Berton O, Wallace-Black D, Nestler EJ: Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biol Psychiatry 54:1317-1329, 2003.
10. Charach A, Ickowicz A, Schachar R: Stimulant treatment over five years: Adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 43:559-567, 2004.
11. Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R: Stimulant treatment over 5 years: Effects on growth. J Am Acad Child Adolesc Psychiatry 45:415-421, 2006.
12. Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD: Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging 30:306-311, 2003.
13. Cochrane C, Malcolm R, Brewerton T: The role of weight control as a motivation for cocaine abuse. Addict Behav 23:201-207, 1998.
14. Comings DE, Rosenthal RJ, Lesieur HR, Rugle LJ, Muhleman D, Chiu C, Dietz G, Gade R: A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics 6:223-234, 1996.
15. Cook EH, Jr., Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL: Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56:993-998, 1995.
16. Davis C, Levitan RD, Kaplan AS, Carter J, Reid C, Curtis C, Patte K, Kennedy JL: Dopamine transporter gene (DAT1) associated with appetite suppression to methylphenidate in a case-control study of binge eating disorder. Neuropsychopharmacology 32:2199-2206, 2007.
17. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D, Bennett ER, Nemanov L, Katz M, Belmaker RH: Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet 12:78-80, 1996.
18. Efron D, Jarman F, Barker M: Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics 100:662-666, 1997.
19. Epstein LH, Leddy JJ: Food reinforcement. Appetite 46:22-25, 2006.
20. Epstein LH, Jaroni JL, Paluch RA, Leddy JJ, Vahue HE, Hawk L, Wileyto EP, Shields PG, Lerman C: Dopamine transporter genotype as a risk factor for obesity in African-American smokers. Obes Res 10:1232-1240, 2002.
21. Epstein LH, Wright SM, Paluch RA, Leddy JJ, Hawk LW Jr, Jaroni JL, Saad FG, Crystal-Mansour S, Shields PG, Lerman C: The relationship between food reinforcement and dopamine genotypes on food intake in smokers. Am J Clin Nutr 80:82-88, 2004.
22. Epstein LH, Leddy JJ, Temple JL, Faith MS: Food reinforcement and eating: A multilevel analysis. Psychol Bull 133:884-906, 2007a.
23. Epstein LH, Temple JL, Neaderhiser BJ, Salis RJ, Erbe RW, Leddy JJ: Food reinforcement, the dopamine D2 receptor genotype, and energy intake in obese and nonobese humans. Behav Neurosci 121:877-886, 2007b.
24. Fabiano GA, Pelham WE, Jr., Waschbusch DA, Gnagy EM, Lahey BB, Chronis AM, Onyango AN, Kipp H, Lopez-Williams A, Burrows-Maclean L: A practical measure of impairment: Psychometric properties of the impairment rating scale in samples of children with attention deficit hyperactivity disorder and two school-based samples. J Clin Child Adolesc Psychol 35:369-385, 2006.
25. Gelernter J, Kranzler HR, Satel SL, Rao PA: Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 11:195-200, 1994.
26. Grandy DK, Zhang Y, Civelli O: PCR detection of the TaqA RFLP at the DRD2 locus. Hum Mol Genet 2:2197, 1993.
27. Gray R, French S, Robinson T, Yeomans M: Dissociation of the effects of preload volume and energy content on subjective appetite and food intake. Physiol Behav 76:57-64, 2002.
28. Gray RW, French SJ, Robinson TM, Yeomans MR: Increasing preload volume with water reduces rated appetite but not food intake in healthy men even with minimum delay between preload and test meal. Nutr Neurosci 6:29-37, 2003.
29. Greenhill L, Beyer DH, Finkleson J, Shaffer D, Biederman J, Conners CK, Gillberg C, Huss M, Jensen P, Kennedy JL, Klein R, Rapoport J, Sagvolden T, Spencer T, Swanson JM, Volkow N: Guidelines and algorithms for the use of methylphenidate in children with attention-deficit/hyperactivity disorder. J Atten Disord 6(Suppl 1):S89-S100, 2002.
30. Hedeker D, Gibbons RD: Application of random-effects patternmixture models for missing data in longitudinal studies. Psycholog Methods 2:64-78, 1997.
31. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, Sedvall GC: Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4:290-296, 1999.
32. Joober R, Grizenko N, Sengupta S, Amor LB, Schmitz N, Schwartz G, Karama S, Lageix P, Fathalli F, Torkaman-Zehi A, Ter Stepanian M: Dopamine transporter 30-UTR VNTR genotype and ADHD: A pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology 32:1370-1376, 2007.
33. Kirley A: The dopamine transporter gene and methylphenidate response in ADHD. Paper presented at: 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP), 2004, Berlin.
34. Kramer JR, Loney J, Ponto LB, Roberts MA, Grossman S: Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems. J Am Acad Child Adolesc Psychiatry 39:517-524, 2000.
35. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K: Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: Effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285:107-110, 2000.
36. Leddy JJ, Epstein LH, Jaroni JL, Roemmich JN, Paluch RA, Goldfield GS, Lerman C: Influence of methylphenidate on eating in obese men. Obes Res 12:224-232, 2004.
37. Lott DC, Kim SJ, Cook EH, Jr., de Wit H: Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 30:602-609, 2005.
38. McGough JJ: Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 57:1367-1373, 2005.
39. McGough JJ, Biederman J, Wigal SB, Lopez FA, McCracken JT, Spencer T, Zhang Y, Tulloch SJ: Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Ad-derall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:530-538, 2005.
40. McGough J, McCracken J, Swanson J, Riddle M, Kollins S, Greenhill L, Abikoff H, Davies M, Chuang S, Wigal T, Wigal S, Posner K, Skrobala A, Kastelic E, Ghuman J, Cunningham C, Shigawa S, Moyzis R, Vitiello B: Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 45:1314-1322, 2006.
41. Mick E, Biederman J, Spencer T, Faraone SV, Sklar P: Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD. Am J Med Genet B Neuropsychiatr Genet 141:890-894, 2006.
42. Mill J, Fisher N, Curran S, Richards S, Taylor E, Asherson P: Polymorphisms in the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. Neuroreport 14:1463-1466, 2003.
43. National Institute of Mental Health: National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: Changes in effectiveness and growth after the end of treatment. Pediatrics 113:762-769, 2004.
44. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ: Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 48:648-654, 1991.
45. Noble EP, Noble RE, Ritchie T, Syndulko K, Bohlman MC, Noble LA, Zhang Y, Sparkes RS, Grandy DK: D2 dopamine receptor gene and obesity. Int J Eat Disord 15:205-217, 1994.
46. Pelham WE, Jr., Gnagy EM, Greenslade KE, Milich R: Teacher ratings of DSM-III-R symptoms for the disruptive behavior disorders. J Am Acad Child Adolesc Psychiatry 31:210-218, 1992.
47. Pelham WE, Aronoff HR, Midlam JK, Shapiro CJ, Gnagy EM, Chronis AM, Onyango AN, Forehand G, Nguyen A, Waxmonsky J: A comparison of Ritalin and Adderall: Efficacy and time-course in children with attention-deficit/ hyperactivity disorder. Pediatrics 103:e43, 1999a.
48. Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, Meichenbaum DL, Williams A, Aronoff HR, Steiner RL: A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics 104:1300-1311, 1999b.
49. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105, 2001.
50. Pelham WE, Burrows-Maclean L, Gnagy EM, Fabiano GA, Coles EK, Tresco KE, Chacko A, Wymbs BT, Wienke AL, Walker KS, Hoffman MT: Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol 13:111-126, 2005a.
51. Pelham WE, Jr., Fabiano GA, Massetti GM: Evidence-based assessment of attention deficit hyperactivity disorder in children and adolescents. J Clin Child Adolesc Psychol 34:449-476, 2005b.
52. Pelham WE, Jr., Manos MJ, Ezzell CE, Tresco KE, Gnagy EM, Hoffman MT, Onyango AN, Fabiano GA, Lopez-Williams A, Wymbs BT, Caserta D, Chronis AM, Burrows-Maclean L, Morse G: A dose-ranging study of a methylphenidate trans-dermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:522-529, 2005c.
53. Pliszka S: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894-921, 2007.
54. Pliszka SR, Matthews TL, Braslow KJ, Watson MA: Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:520-526, 2006.
55. Poulton A: Growth on stimulant medication; clarifying the confusion: A review. Arch Dis Child 90:801-806, 2005.
56. Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, Hutz MH: Attention-deficit hyperactivity disorder: A study of association with both the dopamine transporter gene and the dopamine D4 receptor gene. Am J Med Genet 105:471-478, 2001.
57. Sallis JF, McKenzie TL, Conway TL, Elder JP, Prochaska JJ, Brown M, Zive MM, Marshall SJ, Alcaraz JE: Environmental interventions for eating and physical activity: A randomized controlled trial in middle schools. AmJPrev Med 24:209-217, 2003.
58. Schachter HM, Pham B, King J, Langford S, Moher D: How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165:1475-1488, 2001.
59. Schertz M, Adesman AR, Alfieri NE, Bienkowski RS: Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics 98(Pt 1): 763-769, 1996.
60. Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME: NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): Description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry 39:28-38, 2000.
61. Sobik L, Hutchison K, Craighead L: Cue-elicited craving for food: A fresh approach to the study of binge eating. Appetite 44:253-261, 2005.
62. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S: Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409-432, 1996.
63. Spencer T, Biederman J, Wilens T: Growth deficits in children with attention deficit hyperactivity disorder. Pediatrics 102(Pt 3): 501-506, 1998.
64. Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C, Kim SJ, Cook EH: Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 30:1374-1382, 2005.
65. Swanson J: Compliance with stimulants for attention-deficit/ hyperactivity disorder: Issues and approaches for improvement. CNS Drugs 17:117-131, 2003.
66. Swanson JM, Flodman P, Kennedy J, Spence MA, Moyzis R, Schuck S, Murias M, Moriarity J, Barr C, Smith M, Posner M: Dopamine genes and ADHD. Neurosci Biobehav Rev 24:21-25, 2000.
67. Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, Chuang S, Vitiello B, Skrobala A, Posner K, Abikoff H, Oatis M, McCracken J, McGough J, Riddle M, Ghuman J, Cunningham C, Wigal S: Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 45:1304-1313, 2006.
68. Teicher MH, Polcari A, Foley M, Valente E, McGreenery CE, Chang WW, McKay G, Midha KK: Methylphenidate blood levels and therapeutic response in children with attentiondeficit hyperactivity disorder: I. Effects of different dosing regimens. J Child Adolesc Psychopharmacol 16:416-431, 2006.
69. The MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56:1073-1086, 1999.
70. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, Morris CM, Perry RH, Ferrier IN, Court JA: D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7:479-484, 1997.
71. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614, 1991.
72. Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V: Multiple dopamine D4 receptor variants in the human population. Nature 358:149-152, 1992.
73. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR: Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14:1104-1106, 1992.
74. VanNess SH, Owens MJ, Kilts CD: The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 6:55, 2005.
75. Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, Elliott GR, Hechtman L, Jensen PS, Hinshaw SP, March JS, Newcorn JH, Swanson JM, Cantwell DP: Methylphenidate dosage for children with ADHD over time under controlled conditions: Lessons from the MTA. J Am Acad Child Adolesc Psychiatry 40:188-196, 2001.
76. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N: Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry155:1325-1331, 1998.
77. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D: Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21:RC121, 2001.
78. Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, Solanto MV, Logan J, Wong C, Ma Y, Swanson JM, Schulz K, Pradhan K: Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage 34:1182-1190, 2007.
79. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS: Brain dopamine and obesity. Lancet 357:354-357, 2001.
80. Waxmonsky J: Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness. Curr Opin Pediatr 15:476-482, 2003.
81. Weisler RH: Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder. Expert Opin Pharmacother 8:745-758, 2007.
82. Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, Swanson J, Wigal S, Abikoff H, Kollins S, McCracken J, Riddle M, Posner K, Ghuman J, Davies M, Thorp B, Stehli A: Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 45:1294-1303, 2006.
83. Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, August G, Greenhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M: ADHD treatment with once-daily OROS methylphenidate: Interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 42:424-433, 2003.
84. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M: ADHD treatment with once-daily OROS methylphenidate: Final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 44:1015-1023, 2005.
85. Winsberg BG, Comings DE: Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 38:1474-1477, 1999.
86. Zachor DA, Roberts AW, Hodgens JB, Isaacs JS, Merrick J: Effects of long-term psychostimulant medication on growth of children with ADHD. Res Dev Disabilr 27:162-174, 2006.
87. Zuvekas SH, Vitiello B, Norquist GS: Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 163: 579-585, 2006.